These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 22892289)

  • 21. [Treatment of adult patients with acute promyelocytic leukemia according to the AIDA protocol].
    Parovichnikova EN; Troitskaia VV; Sokolov AN; Kliasova GA; Galstian GM; Kuz'mina LA; Domracheva EV; Dvirnyk VN; Savchenko VG
    Ter Arkh; 2013; 85(7):10-7. PubMed ID: 24137942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Late relapse of acute promyelocytic leukemia treated with all- trans retinoic acid and chemotherapy: report of two cases.
    Ferrara F; Selleri C; Mele G; Serio B; Palmieri S; Pocali B; Pane F; Rotoli B
    Ann Hematol; 2004 Jul; 83(7):484-6. PubMed ID: 14730393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patients from a single institution.
    Pollicardo N; O'Brien S; Estey EH; al-Bitar M; Pierce S; Keating M; Kantarjian HM
    Leukemia; 1996 Jan; 10(1):27-31. PubMed ID: 8558933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks.
    Huang H; Qin Y; Xu R; You X; Teng R; Yang L; Xu M; Liu H
    Leuk Res; 2012 Jul; 36(7):841-5. PubMed ID: 22534100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.
    Shen ZX; Shi ZZ; Fang J; Gu BW; Li JM; Zhu YM; Shi JY; Zheng PZ; Yan H; Liu YF; Chen Y; Shen Y; Wu W; Tang W; Waxman S; De Thé H; Wang ZY; Chen SJ; Chen Z
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5328-35. PubMed ID: 15044693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Morbidity and costs of remission induction therapy with all-trans retinoic acid compared with standard chemotherapy in acute promyelocytic leukemia.
    Eardley AM; Heller G; Warrell RP
    Leukemia; 1994 Jun; 8(6):934-9. PubMed ID: 8207987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.
    Raffoux E; Rousselot P; Poupon J; Daniel MT; Cassinat B; Delarue R; Taksin AL; Réa D; Buzyn A; Tibi A; Lebbé G; Cimerman P; Chomienne C; Fermand JP; de Thé H; Degos L; Hermine O; Dombret H
    J Clin Oncol; 2003 Jun; 21(12):2326-34. PubMed ID: 12805334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disappearance of PML/RAR alpha acute promyelocytic leukemia-associated transcript during consolidation chemotherapy.
    Martinelli G; Ottaviani E; Testoni N; Visani G; Diverio D; D'Elia G; Mandelli F; Tura S
    Haematologica; 1998 Nov; 83(11):985-8. PubMed ID: 9864917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conventional chemotherapy for acute myeloid leukemia: a Brazilian experience.
    Pagnano KB; Traina F; Takahashi T; Oliveira GB; Rossini MS; Lorand-Metze I; Vigorito AC; Miranda EC; De Souza CA
    Sao Paulo Med J; 2000 Nov; 118(6):173-8. PubMed ID: 11120548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective study of a therapeutic regimen with all-trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative study.
    Imaizumi M; Tawa A; Hanada R; Tsuchida M; Tabuchi K; Kigasawa H; Kobayashi R; Morimoto A; Nakayama H; Hamamoto K; Kudo K; Yabe H; Horibe K; Tsuchiya S; Tsukimoto I
    Br J Haematol; 2011 Jan; 152(1):89-98. PubMed ID: 20735397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA.
    Hernández JM; Martín G; Gutiérrez NC; Cervera J; Ferro MT; Calasanz MJ; Martínez-Climent JA; Luño E; Tormo M; Rayón C; Díaz-Mediavilla J; González M; González-San Miguel JD; Pérez-Equiza K; Rivas C; Esteve J; Alvarez Mdel C; Odriozola J; Ribera JM; Sanz MA;
    Haematologica; 2001 Aug; 86(8):807-13. PubMed ID: 11522536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis.
    Wang H; Chen XY; Wang BS; Rong ZX; Qi H; Chen HZ
    Leuk Res; 2011 Sep; 35(9):1170-7. PubMed ID: 21774985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy.
    Breccia M; Diverio D; Noguera NI; Visani G; Santoro A; Locatelli F; Damiani D; Marmont F; Vignetti M; Petti MC; Lo Coco F
    Haematologica; 2004 Jan; 89(1):29-33. PubMed ID: 14754603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Upfront maintenance therapy with arsenic trioxide in acute promyelocytic leukemia provides no benefit for non-t(15;17) subtype.
    Chiang YH; Chang YF; Hsieh RK; Lin J; Chen CG; Lim KH; Lin HC; Chang MC
    Asia Pac J Clin Oncol; 2012 Dec; 8(4):330-6. PubMed ID: 22897350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia.
    Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
    Leuk Res; 2013 Jan; 37(1):37-42. PubMed ID: 23017225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.
    Lengfelder E; Hofmann WK; Nowak D
    Leukemia; 2012 Mar; 26(3):433-42. PubMed ID: 21904379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Long-term therapeutic outcome of patients with acute promyelocytic leukemia].
    Zhang L; Li R; Li DP; Liu YZ; Xu SC; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jan; 28(1):15-8. PubMed ID: 17649719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute promyelocytic leukemia: recent advances in diagnosis and management.
    Lo-Coco F; Ammatuna E; Montesinos P; Sanz MA
    Semin Oncol; 2008 Aug; 35(4):401-9. PubMed ID: 18692690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Stratification therapy in patients with acute promyelocytic leukemia after a complete remission by all-trans retinoic acid].
    Xu JL; Jiang M; Halida Y; Duan XL; Guo XH; Hao JP; Fu ML; Qu JH; Wang L
    Zhonghua Yi Xue Za Zhi; 2011 Aug; 91(32):2254-7. PubMed ID: 22094090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy.
    de Botton S; Coiteux V; Chevret S; Rayon C; Vilmer E; Sanz M; de La Serna J; Philippe N; Baruchel A; Leverger G; Robert A; San Miguel J; Conde E; Sotto JJ; Bordessoule D; Fegueux N; Fey M; Parry A; Chomienne C; Degos L; Fenaux P
    J Clin Oncol; 2004 Apr; 22(8):1404-12. PubMed ID: 15084614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.